Kate Dzintars, Pharm.D., BCPS AQ-ID

Kate Dzintars, PharmD, BCPS AQ-ID

Associate Pharmacy Director, Adult Antimicrobial Stewardship Program

Education and Training
Professional Memberships
Clinical and Research Interests
Selected Publications
Contact Information

Education and Training

Pharm.D., University of Pittsburgh, Pittsburgh, PA (2003)
Pharmacy Practice Residency, University Health System, San Antonio, TX (2004)
Infectious Diseases Pharmacy Residency, South Texas Veterans Healthcare System, San Antonio, TX (2005)

Professional Memberships

Infectious Diseases Society of America
Society for Healthcare Epidemiology of America
Society of Infectious Disease Pharmacists
American Society of Health-System Pharmacists
Maryland Society of Health-System Pharmacy

Clinical and Research Interests

Dr. Dzintars’ clinical and research interests include outcomes related to antimicrobial stewardship, management of infections in the immunosuppressed population, antifungal use and Gram-negative resistance.

Selected Publications

  1. Keller SC, Dzintars K, Gorski LA, Williams D, Cosgrove SE. Antimicrobial Agents and Catheter Complications in Outpatient Parenteral Antimicrobial Therapy. Pharmacotherapy 2018;38(4):476-81. 
  2. Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of Adverse Events with Antibiotic Use in Hospitalized Patients. JAMA Intern Med 2017;177(9):1038-15.
  3. Shoulders BR, Crow JR, Davis SL, Whitman GJ, Gavin M, Lester L, Barodka V, Dzintars K. Impact of intraoperative continuous-infusion versus intermittent dosing of cefazolin therapy on the incidence of surgical site infections after coronary artery bypass grafting. Pharmacotherapy. 2016; 36(2):166-73.
  4. Lewis JS 2nd, Lepak AJ, Thompson GR 3rd, Craig WA, Andes DR, Dzintars K, Jorgensen JH. Failure of clindamycin to eradicate infection with beta-hemolytic streptococci inducibly resistant clindamycin in an animal model and human infections. Antimicrobial Agents Chemother. 2014; 58(3):1327-31.
  5. Oates E, Dzintars K. Interaction between enfuvirtide, an injectable fusion inhibitor, and niacin in an HIV-infected patient. Ann Pharmacother. 2010; 44(12):2014-7.
  6. Sabol KE, Gumbo T. Anidulafungin in the treatment of invasive fungal infections. Ther Clin Risk Manag. 2008; 4(1):71-8.
  7. Sabol KE, Echevarria KL, Lewis JS 2nd. Community-associated methicillin-resistant Staphylococcus aureus: new bug, old drugs. Ann Pharmacother. 2006; 40(6):1125-33.
  8. Lewis JS 2nd, Owens A, Cadena J, Sabol KE, Patterson JE, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrobial Agents Chemother. 2005; 49(5):2152.
  9. Dzintars K, Toman LP. Interpretation and Understanding of Clinical Drug Interactions Between Azoles and Immunosuppressants in Solid Organ Transpant Recipients. Current Fungal Infection Reports2020;14:391-6.
  10. Thom KA, Tamma PD, Harris AD, Dzintars K, Morgan DJ, Li S, Pineles L, Srinivasan A, Avdic E, Cosgrove SE. Impact of a prescriber-driven antibiotic time-out on antibiotic use in hospitalized patients. Clin Infect Dis 2019;68(9);1581-4.
  11. Fabre V, Markou T, Sick-Samuels A, Rock C, Avdic E, Shulder S, Dzintars K, Saunders H, Andonian J, Cosgrove SE. Impact of case-specific education and face-to-face feedback to prescribers and nurses in the management of hospitalized patients with a positive Clostridium difficile test. Open Forum Infect Dis 2018;5:1-6.
  12. Fabre MV, Dzintars K, Avdic E, Cosgrove SE. Role of metronidazole in mild Clostridium difficile infections. Clin Infect Dis 2018;67(12):1956-8.

Contact Information

600 North Wolfe Street, Halsted 837
Baltimore, MD 21287

Phone: 443-287-4570
Email:[email protected]